Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma appoints head of regulatory affairs

Rizwana Sproule joins from Amgen
Kite Pharma Rizwana Sproule

Kite Pharma has appointed former Amgen executive director Dr Rizwana Sproule as head VP, regulatory affairs.

Dr Sproule spent 14 year at Amgen, most recently serving as executive director, therapeutic area head for oncology global regulatory affairs.

In this role, she oversaw Amgen's oncology products having previously held the role of global regulatory leader for the development of Amgen's Vectibix (panitumumab), which is approved to treat colorectal cancer.

Her experience prior to joining Amgen includes a regulatory affairs consultant role at the clinical research organisation (CRO) Kendle, as well as roles at SmithKline Beecham and Syntex.

Kite's chairman Dr Arie Belldegrun said: "Rizwana offers an impressive track record in guiding the regulatory process for well-recognised best-in-class therapies, and her expertise in working with international agencies – FDA, EMA/CHMP, Health Canada, and PMDA – at multiple levels will be critical to Kite's further advancement and planning.”

Dr Sproule is the latest in a string of senior appointments at Kite as the company prepares for the advance of its research projects involving cancer immunotherapies.

Other recent additions include chief financial officer Cynthia Butitta; Dr Keith Nolop as chief medical officer; and several cancer experts to the company's scientific advisory board.

22nd January 2014

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics